Founded on the principles of scientific excellence and a passion for making a positive impact on global health, Vincere Biosciences has emerged as a key player in the life-sciences sphere. Vincere Biosciences focuses its research on the vital role of mitophagy in both Parkinson’s disease and the ageing process. Its cutting-edge research addresses deficient mitophagy in a mission to bring in a new era of groundbreaking treatment. As a resident of Johnson & Johnson Innovation-JLABS and with support from major expert agencies, Vincere Biosciences is well positioned to advance its research of small molecules toward clinical translation.
Vincere Biosciences began working with FreeMind Group in 2021, in order to start their journey toward receiving non-dilutive funding for their pipeline of progects, including small molecules designed to boost mitophagy, with the potential to become the first ever medicines capabile of either slowing or stopping Parkinson’s disease and other age-related conditions.
As Vincere Biosciences continues to make strides in biomedical innovation, the future holds exciting possibilities. With a strong foundation built on scientific expertise, a commitment to patients, and a collaborative spirit, Vincere BioSciences is well-positioned to contribute significantly to the advancement of healthcare.
“We are deeply honored to be recognized as a ‘Freemind Elite’ partner. Our collaboration with Freemind Group has been instrumental in our success, helping us secure crucial non-dilutive funding. We are proud of this partnership and look forward to continuing our journey together in pioneering groundbreaking solutions in the biosciences sector.”